Home
IVVD
IVVD News

Latest Invivyd Inc. (IVVD) News on December 22, 2024

Adagio Medical announces Todd Usen as new CEO and director

Medical Device Network

5 days ago

Adagio Medical announces Todd Usen as new CEO and director

MT Newswires

6 days ago

Adagio Medical Appoints Todd Usen as CEO

Thomson Reuters StreetEvents

a month ago

Q3 2024 Invivyd Inc Earnings Call

GuruFocus.com

a month ago

Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Zacks

a month ago

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

a month ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

GlobeNewswire

a month ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect

GuruFocus.com

a month ago

Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

GlobeNewswire

a month ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

GlobeNewswire

2 months ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

GlobeNewswire

2 months ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

MT Newswires

2 months ago

Invivyd Shares Fall After Revenue Guidance Withdrawal

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

GlobeNewswire

2 months ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

GlobeNewswire

2 months ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

GlobeNewswire

2 months ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

GlobeNewswire

3 months ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

MT Newswires

3 months ago

Invivyd Provides Virology Data Supporting Pemivibart's Effectiveness Against Current SARS-CoV-2 Variants

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

GlobeNewswire

3 months ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Simply Wall St.

3 months ago

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

GlobeNewswire

3 months ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Invivyd to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

GlobeNewswire

4 months ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

GlobeNewswire

4 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

MT Newswires

4 months ago

Invivyd's Covid-19 Antibody Shows 84% Risk Reduction in Phase 3 Trial; Shares Fall

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

GlobeNewswire

4 months ago

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Thomson Reuters StreetEvents

4 months ago

Q2 2024 Invivyd Inc Earnings Call

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Zacks

4 months ago

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

4 months ago

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

4 months ago

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

MT Newswires

6 months ago

Invivyd Joining Russell 2000, 3000 Indexes

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

GlobeNewswire

6 months ago

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future

Simply Wall St.

6 months ago

Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

GlobeNewswire

6 months ago

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Invivyd to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire

7 months ago

Invivyd to Participate at the Jefferies Global Healthcare Conference

MT Newswires

7 months ago

Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

GlobeNewswire

7 months ago

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

GlobeNewswire

7 months ago

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

GlobeNewswire

7 months ago

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire

7 months ago

Invivyd Elects Two New Independent Members to its Board of Directors

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

GlobeNewswire

7 months ago

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript

Insider Monkey

7 months ago

Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript

With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest

Simply Wall St.

7 months ago

With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest

GuruFocus.com

7 months ago

Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

7 months ago

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

GlobeNewswire

8 months ago

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

8 months ago

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

GlobeNewswire

8 months ago

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

GlobeNewswire

8 months ago

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Invivyd Announces CEO Transition

GlobeNewswire

8 months ago

Invivyd Announces CEO Transition

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Simply Wall St.

8 months ago

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

GlobeNewswire

9 months ago

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire

9 months ago

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

GlobeNewswire

9 months ago

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

GlobeNewswire

9 months ago

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Best Value Stocks to Buy for February 1st

Zacks

a year ago

Best Value Stocks to Buy for February 1st

Senate tells social media CEOs they have 'blood on their hands' for failing to protect children

Engadget

a year ago

Senate tells social media CEOs they have 'blood on their hands' for failing to protect children

3 Groundbreaking Biotech Stocks to Invest in Now

InvestorPlace

a year ago

3 Groundbreaking Biotech Stocks to Invest in Now

GlobeNewswire

a year ago

Simplicity Group Unveils WeDYOR: Transforming Due Diligence for Crypto Investments

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

GlobeNewswire

a year ago

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

Is There An Opportunity With Metals Acquisition Limited's (NYSE:MTAL) 35% Undervaluation?

Simply Wall St.

a year ago

Is There An Opportunity With Metals Acquisition Limited's (NYSE:MTAL) 35% Undervaluation?

Virtu Financial Inc (VIRT) Reports Mixed Fourth Quarter and Full Year 2023 Results

GuruFocus.com

a year ago

Virtu Financial Inc (VIRT) Reports Mixed Fourth Quarter and Full Year 2023 Results

Eagle Bancorp Inc (EGBN) Reports Q4 2023 Earnings: Net Income Declines to $20.2 Million

GuruFocus.com

a year ago

Eagle Bancorp Inc (EGBN) Reports Q4 2023 Earnings: Net Income Declines to $20.2 Million

Amerant Reports Fourth Quarter 2023 and Full-Year 2023 Results

Business Wire

a year ago

Amerant Reports Fourth Quarter 2023 and Full-Year 2023 Results

Alexander & Baldwin Announces Fourth Quarter and Full-Year 2023 Earnings Release and Conference Call Date

PR Newswire

a year ago

Alexander & Baldwin Announces Fourth Quarter and Full-Year 2023 Earnings Release and Conference Call Date

3 Lithium Stocks to Turn $10,000 Into $1 Million: January 2024

InvestorPlace

a year ago

3 Lithium Stocks to Turn $10,000 Into $1 Million: January 2024

Lithium Americas Stock (NYSE:LAC): Positioned to Profit from an EV Boom

TipRanks

a year ago

Lithium Americas Stock (NYSE:LAC): Positioned to Profit from an EV Boom

15 Small-Cap Stocks with High Potential

Insider Monkey

a year ago

15 Small-Cap Stocks with High Potential

Northwest Bancshares (NWBI) Matches Q4 Earnings Estimates

Zacks

a year ago

Northwest Bancshares (NWBI) Matches Q4 Earnings Estimates

When Will Invivyd, Inc. (NASDAQ:IVVD) Become Profitable?

Simply Wall St.

a year ago

When Will Invivyd, Inc. (NASDAQ:IVVD) Become Profitable?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 36% Undervaluation?

Simply Wall St.

a year ago

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 36% Undervaluation?

Amerant Bancorp Inc. Declares Dividend

Business Wire

a year ago

Amerant Bancorp Inc. Declares Dividend

Radware Expands DDoS Protection for World Leading Telecom

GlobeNewswire

a year ago

Radware Expands DDoS Protection for World Leading Telecom

10 Small-Cap Energy Stocks with Strong Returns

Insider Monkey

a year ago

10 Small-Cap Energy Stocks with Strong Returns

VINCI PARTNERS TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2023 RESULTS AND HOST WEBCAST AFTER MARKET CLOSE ON WEDNESDAY, FEBRUARY 07, 2024

PR Newswire

a year ago

VINCI PARTNERS TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2023 RESULTS AND HOST WEBCAST AFTER MARKET CLOSE ON WEDNESDAY, FEBRUARY 07, 2024

AdvanSix to Release Fourth Quarter Financial Results and Hold Investor Conference Call on February 16

Business Wire

a year ago

AdvanSix to Release Fourth Quarter Financial Results and Hold Investor Conference Call on February 16

Retail Tech: Alibaba’s AI Sourcing Update, Ikea’s Demand Sensing Collab

Sourcing Journal

a year ago

Retail Tech: Alibaba’s AI Sourcing Update, Ikea’s Demand Sensing Collab

We Ran A Stock Scan For Earnings Growth And Skyward Specialty Insurance Group (NASDAQ:SKWD) Passed With Ease

Simply Wall St.

a year ago

We Ran A Stock Scan For Earnings Growth And Skyward Specialty Insurance Group (NASDAQ:SKWD) Passed With Ease

All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy

Zacks

a year ago

All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy

Enviri Corporation Announces Timing Of Fourth Quarter And Full Year 2023 Results And Conference Call

GlobeNewswire

a year ago

Enviri Corporation Announces Timing Of Fourth Quarter And Full Year 2023 Results And Conference Call

Stagwell (STGW) and MNTN Partner to Forge a Unified Performance Marketing Ecosystem for Brands

PR Newswire

a year ago

Stagwell (STGW) and MNTN Partner to Forge a Unified Performance Marketing Ecosystem for Brands

At US$61.47, Is It Time To Put Bel Fuse Inc. (NASDAQ:BELF.A) On Your Watch List?

Simply Wall St.

a year ago

At US$61.47, Is It Time To Put Bel Fuse Inc. (NASDAQ:BELF.A) On Your Watch List?

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

GlobeNewswire

a year ago

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

3 Stellar Stocks That Could Make You a Millionaire by 2026

InvestorPlace

a year ago

3 Stellar Stocks That Could Make You a Millionaire by 2026

Is Summit Hotel Properties (INN) Stock Undervalued Right Now?

Zacks

a year ago

Is Summit Hotel Properties (INN) Stock Undervalued Right Now?

Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?

Motley Fool

a year ago

Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

Zacks

a year ago

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

Despegar.com, Corp.'s (NYSE:DESP) Share Price Matching Investor Opinion

Simply Wall St.

a year ago

Despegar.com, Corp.'s (NYSE:DESP) Share Price Matching Investor Opinion

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

GlobeNewswire

a year ago

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

3 Innovative Russell 2000 Stocks to Watch in 2024

InvestorPlace

a year ago

3 Innovative Russell 2000 Stocks to Watch in 2024

Despegar.com Raises 2023 Financial Guidance

Business Wire

a year ago

Despegar.com Raises 2023 Financial Guidance

Secureworks and SentinelOne® Deliver Trailblazing Global Joint Go-To-Market Program to Decrease Cyber Risk

PR Newswire

a year ago

Secureworks and SentinelOne® Deliver Trailblazing Global Joint Go-To-Market Program to Decrease Cyber Risk

Here's Why We Think Amalgamated Financial (NASDAQ:AMAL) Might Deserve Your Attention Today

Simply Wall St.

a year ago

Here's Why We Think Amalgamated Financial (NASDAQ:AMAL) Might Deserve Your Attention Today

NNN REIT (NNN) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

a year ago

NNN REIT (NNN) Upgraded to Buy: What Does It Mean for the Stock?

Insider Sell Alert: Criteo SA's Chief Legal Officer Ryan Damon Offloads 8,804 Shares

GuruFocus.com

a year ago

Insider Sell Alert: Criteo SA's Chief Legal Officer Ryan Damon Offloads 8,804 Shares

CleanSpark, Inc. (NASDAQ:CLSK) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

CleanSpark, Inc. (NASDAQ:CLSK) Q4 2023 Earnings Call Transcript

Hibbett (NASDAQ:HIBB) Has Affirmed Its Dividend Of $0.25

Simply Wall St.

a year ago

Hibbett (NASDAQ:HIBB) Has Affirmed Its Dividend Of $0.25

First Trust Intermediate Duration Preferred & Income Fund Increases its Monthly Common Share Distribution to $0.1375 Per Share for December

Business Wire

a year ago

First Trust Intermediate Duration Preferred & Income Fund Increases its Monthly Common Share Distribution to $0.1375 Per Share for December

Share on Social Networks: